Overview

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (metformin) throughout the study.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Exenatide
Metformin